Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Inflammatory Bowel Disease I: Ulcerative Colitis

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

Cytomegalovirus Disease

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind Trial.

Open forum infectious diseases·2023

Same author

The Relationship Between Antibiotic Agent and Mortality in Patients With Febrile Neutropenia due to Staphylococcal Bloodstream Infection: A Multicenter Cohort Study.

Open forum infectious diseases·2022

Same author

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.

Blood advances·2022

Same author

Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States.

Transplant infectious disease : an official journal of the Transplantation Society·2022

Same author

Audio Interview: Do We Need New Covid-19 Vaccines?

The New England journal of medicine·2022

Same author

Bacteriophage treatment of disseminated cutaneous Mycobacterium chelonae infection.

Nature communications·2022

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Biological Compatibility Profile on Biomaterials for Bone Regeneration

Published on: November 16, 2018

Infectious complications associated with immunomodulating biologic agents.

Sophia Koo¹, Francisco M Marty, Lindsey R Baden

¹Division of Infectious Diseases, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA.

Hematology/Oncology Clinics of North America

|January 18, 2011

Summary

This summary is machine-generated.

Biologic therapies targeting the immune system are increasing. This review details infectious complications linked to US Food and Drug Administration-approved immunomodulating biologics.

More Related Videos

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Related Experiment Videos

Last Updated: Jun 5, 2026

Biological Compatibility Profile on Biomaterials for Bone Regeneration

Published on: November 16, 2018

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Assessment of Antibody-based Drugs Effects on Murine Bone Marrow and Peritoneal Macrophage Activation

Published on: December 26, 2017

Area of Science:

Immunology
Infectious Diseases
Pharmacology

Background:

The development of biologic therapies has revolutionized treatment for various immune-mediated conditions.
These therapies target specific immune system components, offering precise therapeutic effects.
The expanding use of biologics necessitates a thorough understanding of their associated risks.

Purpose of the Study:

To comprehensively review infectious complications associated with immunomodulating biologic therapies.
To categorize these complications based on the specific biologic agent used.
To provide an updated overview for clinicians and researchers regarding safety profiles.

Main Methods:

Systematic literature search for studies on biologic therapies and infectious complications.
Inclusion of US Food and Drug Administration-approved immunomodulating biologics.
Categorization of infectious complications by drug class and mechanism of action.

Main Results:

Biologic therapies targeting different immune pathways present distinct infectious risk profiles.
Common infections include opportunistic pathogens and reactivation of latent infections.
Specific biologic classes are associated with particular types of infectious complications.

Conclusions:

Understanding the spectrum of infectious complications is crucial for safe biologic therapy use.
Risk stratification and proactive monitoring can mitigate infectious risks.
Continued surveillance is necessary as new biologic agents emerge.